Discovery of an orally bioavailable alkyl oxadiazole β3 adrenergic receptor agonist
- 1 July 2000
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 10 (13) , 1427-1429
- https://doi.org/10.1016/s0960-894x(00)00267-5
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Potent, selective human β3 adrenergic receptor agonists containing a substituted indoline-5-sulfonamide pharmacophoreBioorganic & Medicinal Chemistry Letters, 1999
- L-770,644: A potent and selective human β3 adrenergic receptor agonist with improved oral bioavailabilityBioorganic & Medicinal Chemistry Letters, 1999
- Human β3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamidesBioorganic & Medicinal Chemistry Letters, 1999
- 3-pyridylethanolamines: Potent and selective human β3 adrenergic receptor agonistsBioorganic & Medicinal Chemistry Letters, 1998
- Potent, selective benzenesulfonamide agonists of the human β3 adrenergic receptorBioorganic & Medicinal Chemistry Letters, 1998
- An improved oxadiazole synthesis using peptide coupling reagentsTetrahedron Letters, 1996
- New publicationsPsychiatric Bulletin, 1996
- The potential role of β3 adrenoceptor agonists In the treatment of obesity and diabetesCurrent Opinion in Endocrinology, Diabetes and Obesity, 1996
- Chapter 20. β3-Selective Adrenergic Receptor AgonistsPublished by Elsevier ,1995
- β3 and Atypical β‐AdrenoceptorsMedicinal Research Reviews, 1993